Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 30 December 2025 - 12 January 2026

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
12 January 2026
······
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI shares rose about 11% in premarket trading Monday after the company reported preliminary 2025 revenue of $1.27 billion, up 83% year-on-year, and record contract value exceeding $1.1 billion. The company cited strong growth in both Diagnostics and Data segments, with over 70 new data agreements signed in 2025. Tempus noted the results are unaudited and subject to change.
12 January 2026
·······
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer shares rose 0.3% to $25.36 after a U.S. appeals court blocked a Trump-era pilot that would have changed drug payments for safety-net hospitals. The ruling affects drugs like Eliquis, co-marketed by Pfizer and Bristol Myers Squibb. Investors await Pfizer CEO Albert Bourla’s update at the J.P. Morgan Healthcare Conference on Jan. 12. Pfizer reports earnings Feb. 3, with COVID sales and patent losses in focus.
8 January 2026
··
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Bayer’s Monsanto filed a lawsuit against Pfizer, BioNTech, and Moderna in Delaware federal court, alleging misuse of mRNA technology patents. Pfizer shares rose 0.9% to $25.67 in early trading after UBS began coverage with a Neutral rating and a $25 price target. Investors are watching for Pfizer’s Q4 and full-year 2025 results on February 3.
7 January 2026
····
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer shares closed up 1.1% at $25.18 on Friday, after leading U.S. drugmakers in January list-price hikes, including a 15% increase for its COVID vaccine Comirnaty. The stock remains below its 52-week high of $27.69. Investors await Pfizer’s Feb. 3 earnings update and monitor upcoming U.S. jobs and inflation data.
3 January 2026
····
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

U.S. drugmakers are raising list prices on at least 350 branded medicines for 2026, with a median increase of about 4%, Reuters reported. The Health Care Select Sector SPDR Fund (XLV) closed up 0.46% at $155.51 Friday. Pfizer, Eli Lilly, and Johnson & Johnson all posted gains. Traders are watching next week’s U.S. jobs data and upcoming healthcare earnings.
3 January 2026
····
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson closed Friday up 0.19% at $207.35 after declaring a $1.30-per-share quarterly dividend, payable March 10 to shareholders of record as of Feb. 24. The stock traded between $203.68 and $207.37 during the session. Investors await J&J’s Jan. 21 earnings call and next week’s U.S. labor data. The S&P 500 finished up 0.19%.
3 January 2026
·····
Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer shares rose 0.8% to $25.09 Friday amid renewed focus on U.S. drug pricing after reports of 2026 list-price hikes, including a 15% increase for its COVID-19 vaccine. A Reuters report said Pfizer will lead price increases on about 80 drugs, though most hikes are under 10%. Investors await Pfizer’s next quarterly update on February 3. Trading volume reached about 20.7 million shares.
2 January 2026
··
Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

Pfizer shares fell 0.4% to $24.90 in premarket trading Friday after Reuters reported the company plans to raise U.S. list prices on about 80 medicines in 2026, including a 15% hike for COVID-19 vaccine Comirnaty. The moves come as drugmakers face pressure from the Trump administration to lower prices and as investors await Pfizer’s February 3 results update.
2 January 2026
··
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer shares slipped 0.4% to $24.90 after hours following a report the company will raise U.S. list prices on about 80 medicines in 2026, including a 15% hike for its COVID vaccine Comirnaty. Most Pfizer increases are under 10%. U.S. stock markets were closed Thursday for New Year’s Day. Investors await Pfizer’s Feb. 3 results and 2026 outlook.
1 January 2026
···
Pfizer stock today: PFE in focus as 2026 U.S. drug price hikes kick off — what to watch next

Pfizer stock today: PFE in focus as 2026 U.S. drug price hikes kick off — what to watch next

NEW YORK, January 1, 2026, 05:20 ET — Market closed. Pfizer Inc (NYSE:PFE) is in focus after annual U.S. drug pricing changes for 2026 included increases on some of its medicines, a politically sensitive topic heading into the new year. Pfizer shares last closed down 0.36% at $24.90 on Wednesday after trading between $24.88 and $25.02, with about 29.4 million shares changing hands. The price resets typically arrive on Jan. 1, when manufacturers post higher list prices — the sticker price before rebates — for many branded drugs. This year’s round is landing as the Trump administration keeps pressure on
1 January 2026
··
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer shares fell 0.4% to $24.90 in after-hours trading after reports the company will lead U.S. drug list-price increases in 2026, including a 15% hike for its COVID vaccine. Healthcare data show Pfizer plans about 80 price increases, as drugmakers prepare for the annual January price reset under political scrutiny. Investors await further pricing updates and Pfizer’s February earnings call.
1 January 2026
···
Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

NEW YORK, December 30, 2025, 19:40 ET — After-hours Pfizer Inc. shares were little changed in late after-hours trading on Tuesday, down about 0.02% at $24.99, after moving between $24.92 and $25.10 in the regular session. After-hours trading is the session after the 4 p.m. ET close, when volumes can be thinner and moves can be sharper. The quiet tape does not mean investors have gone quiet on Pfizer. Traders have been treating the stock as a test case for whether Big Pharma can defend cash flows as pandemic-era sales fade and older blockbusters face cheaper rivals. That backdrop has
31 December 2025
···
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer shares edged up 0.1% to $25.03 Tuesday after TD Cowen reiterated a Hold rating and $30 price target, citing negative trends through 2030. The company projected 2026 revenue of $59.5 billion to $62.5 billion and warned of a “bumpy” period ahead as COVID demand fades and key patents expire. Shares have dropped over 50% since early 2023. Pfizer’s next earnings report is set for February 3.
30 December 2025
··
1 2 3 4 5 … 7

Stock Market Today

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
GE Vernova stock closes up nearly 6% — what to watch before Monday’s trade

GE Vernova stock closes up nearly 6% — what to watch before Monday’s trade

7 February 2026
GE Vernova shares jumped 5.6% to $779.35 Friday as Wall Street rallied and the company reported 1.1 GW of U.S. wind repower orders for 2025. The company also closed its $5.3 billion purchase of the remaining Prolec GE stake and completed a $2.6 billion senior notes offering. Investors await next week’s U.S. jobs and inflation data.
Go toTop